
A trial cannot become more accessible simply by moving its paperwork online. The benefits of decentralized clinical trials arise when sponsors identify which activities participants can complete safely and reliably outside a traditional research site, then design the supporting clinical and digital workflows around those decisions.
For clinical operations teams, this is less about replacing sites than about choosing where each assessment, consent discussion, or data collection step works best. The resulting model may be site-based with selected remote elements, hybrid, or predominantly remote.
Why the Benefits of Decentralized Clinical Trials Depend on Design
Decentralization is an operational choice, not a separate standard of evidence. The U.S. Food and Drug Administration’s (FDA) September 2024 final guidance describes decentralized elements as trial-related activities conducted away from traditional sites, including telehealth visits, home visits, and encounters with local healthcare providers. Its recommendations cover drugs, biological products, and medical devices. [1]
The FDA also makes clear that the regulatory requirements for trials with decentralized elements are the same as those for other clinical trials. That distinction matters: moving an activity changes where and how teams coordinate it, not who remains accountable for participant safety and reliable evidence.
In decentralized research, a sponsor should therefore start with the protocol’s critical data, safety procedures, and participant needs. Only then should the team decide which steps can take place remotely and what technology and oversight those steps require.
Participation Benefits of Decentralized Clinical Trials: Fewer Travel Demands
Reducing the need for repeated site visits may make participation feasible for people who would otherwise decline or struggle to continue. Travel distance, time away from work, caregiving responsibilities, disability, and access to transportation all shape the practical burden of participation.
For a participant who needs frequent symptom assessments but only occasional physical examinations, electronic questionnaires completed away from the site may be more convenient than traveling for every follow-up. Local laboratory services or telehealth may also be appropriate, depending on the protocol and jurisdiction.
A 2023 systematic review examined 13 studies involving decentralized recruitment approaches. Eleven reported improved recruitment, including seven that directly compared decentralized and traditional methods. These are encouraging findings, but the evidence base was relatively small and heterogeneous; no sponsor should assume the same effect in every study. [2]
The practical takeaway is to distinguish access from enrollment. A wider geographic reach may broaden who can consider a trial, but actual enrollment still depends on eligibility, awareness, trust, digital access, and suitable support. Remote options should expand participant choice rather than replace necessary personal contact.
Consider a hypothetical multi-site device study with long-term follow-up. Participants might attend sites for device-related procedures and imaging while completing selected patient-reported assessments remotely between visits. This hybrid model could reduce unnecessary travel without moving safety-critical procedures away from qualified facilities.
Data Collection Benefits of Decentralized Clinical Trials
Electronic patient-reported outcomes (ePRO) and electronic clinical outcome assessments (eCOA) can support data collection beyond scheduled site visits. ePRO captures information reported directly by participants electronically, while eCOA is a broader category that also encompasses other electronically captured clinical outcome assessments. For a closer look at the data quality side, see how a dedicated ePRO app can strengthen patient data quality.
When appropriate for the instrument and protocol, remote questionnaires may allow participants to record symptoms or functioning closer to their everyday experience. This may lessen reliance on retrospective recall and support more frequent assessment, although completion rates and data quality depend on usability, training, and study procedures.
The design questions are concrete:
- Does the assessment need to be completed at a defined time or within a visit window?
- Is its electronic format suitable for the intended measurement and population?
- What happens if participants miss entries or lose connectivity?
- Who reviews reported concerns, and when does a response require clinical escalation?
- How will the study track data provenance and reconcile information across systems?
Remote decentralized clinical trials also need a plan for participants who cannot or prefer not to use a personal device. The FDA’s 2024 guidance recommends that, when participants are permitted to use their own digital health technologies (DHTs), sponsor-provided DHTs should also be available as an option. It also recommends making sponsor-provided telecommunication services available as needed, so that participants with no or limited access are not excluded. [1]
European regulatory recommendations place similar emphasis on participant choice, accessibility, and continued access to in-person care. The October 2025 Recommendation Paper on Decentralised Elements in Clinical Trials, developed through a joint initiative of the European Commission, the European Medicines Agency (EMA), and the Heads of Medicines Agencies, recommends that participants undertaking trial-related procedures at home have the opportunity to visit the investigator in person when needed or preferred. It also recommends providing a direct contact line for additional support and alternatives for participants who are unable or unwilling to use their own devices for trial data collection. These nonbinding recommendations apply to clinical trials of medicinal products in the EU/EEA. [3]
Together, the FDA and European recommendations reinforce the importance of designing decentralized activities around participants’ individual needs, with appropriate technological support, access to in-person interactions, and contingency arrangements where necessary.
Importantly, electronic assessments are not inherently decentralized: ePRO or eCOA can also be administered during an in-person site visit. The benefit comes from fitting collection methods to the study rather than treating technology itself as the endpoint.
Which Trial Model Fits the Protocol?
Most decentralized studies do not need to move every activity outside the site. The FDA guidance notes that trials requiring complex medical assessments or investigational product administration may still need in-person visits, with selected follow-up assessments conducted remotely. [1] This is the logic behind a hybrid clinical trial model, where site and remote activities are planned together.
| Trial approach | Suitable activities | Key operational consideration | Potential value |
| Primarily site-based | Procedures, complex assessments, supervised interventions | Travel demands and site scheduling | Direct clinical supervision for site-dependent tasks |
| Hybrid with decentralized elements | Remote ePRO, selected follow-up visits, local services, and site assessments | Coordination across remote and in-person workflows | May reduce visits while preserving necessary site involvement |
| Predominantly remote | Activities that can be performed safely and reliably away from a site | Remote oversight, access, safety escalation, and data verification | May extend geographic participation where the protocol permits |
The comparison should be made at the activity level rather than the trial-label level. A sponsor can use a hybrid design for one endpoint while retaining traditional site procedures for another.
Imagine a hypothetical outpatient therapeutic study where participants can submit routine symptom reports from home, but protocol-defined laboratory tests require controlled handling. Electronic reporting may be suitable between visits, while local or site-based sample collection remains necessary.
Procurement should test actual workflows, from consent and data capture to oversight and reconciliation.

How Catchtrial Apps+ Supports Decentralized Study Workflows
A decentralized strategy depends on reliable participant-facing processes as much as on remote visit options. Catchtrial Apps+, part of Medigen Suite, includes ePRO, eCOA, and eConsent modules that are relevant to participant-reported assessments and electronic consent processes.
For studies incorporating selected remote activities, these modules are designed to support electronic collection and documentation in workflows that can be planned around the protocol. Their potential value lies in supporting a structured approach to participant-facing data and consent alongside the broader clinical trial operation.
Three questions help connect software evaluation to study needs:
- Participant experience: Can the intended consent and assessment process accommodate participants’ languages, abilities, and device access?
- Data operations: How will captured information be reviewed, queried where appropriate, and transferred or reconciled with electronic data capture (EDC) and other study records?
- Oversight: Which responsibilities, escalation pathways, access controls, and records will the sponsor need to configure and verify?
Medigen Suite also includes Catchtrial EDC+ and Maptrial CTMS+ within its broader eClinical portfolio. Sponsors should evaluate required interfaces, configured workflows, and validation evidence for their specific implementation rather than assume any particular integration or automation is available by default.
The goal is not to make every study virtual. It is to choose a participant-facing approach that supports the protocol and can be operated consistently by sites and study teams.
For an overview of the available participant-facing modules, visit the Catchtrial Apps+ product page.

Regulatory Oversight Still Applies Outside the Trial Site
Remote trial activities do not transfer regulatory accountability to the participant or the software vendor. FDA guidance addresses investigator oversight, local healthcare provider roles, informed consent, safety monitoring, digital technology, and data integrity when decentralized elements are used. [1]
Electronic informed consent must still meet applicable consent requirements. FDA and the U.S. Office for Human Research Protections have published guidance on using electronic systems in the informed consent process, including the need to support participant understanding and questions. [4] These requirements are also a useful checklist when choosing the right eConsent platform.
Where FDA’s 21 CFR Part 11 applies to electronic records and signatures, relevant controls must be addressed. FDA’s October 2024 final guidance on electronic systems further discusses the trustworthiness and reliability of electronic records and signatures used in clinical investigations. [5]
ICH E6(R3) Good Clinical Practice emphasizes quality by design, proportionate risk management, participant protection, and reliable results in applicable drug trials. Its Annex 2, adopted by ICH on June 3, 2026, adds GCP considerations specifically for trials incorporating decentralized elements, pragmatic elements, and real-world data sources. Annex 2 was subsequently adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on June 25, 2026, and is scheduled to become effective in the EU on January 15, 2027. [6]
The European Commission, European Medicines Agency, and Heads of Medicines Agencies also maintain recommendations on decentralized elements, updated in October 2025, for the EU/EEA medicinal-product trial context. [3]
Sponsors running multinational or medical device studies must separately assess the rules applicable to each country and study type. Data protection obligations, including the EU General Data Protection Regulation (GDPR) where applicable, remain relevant to remote collection and transfers.
Start With the Activities That Matter Most
A useful decentralized plan starts with a map of participant burden and critical trial procedures. Identify which visits need direct clinical assessment, which questionnaires can be completed electronically, and which activities require local services or trained personnel.
Then pilot the proposed workflows with appropriate users, define exceptions and escalation routes, and verify how documentation and data reach the responsible teams. Monitor completion patterns, participant feedback, protocol deviations, and data quality throughout the study so adjustments are evidence-based.
The benefits of decentralized clinical trials depend on choices that are operationally credible for the specific protocol. To assess whether Catchtrial Apps+ fits your planned ePRO, eCOA, or eConsent workflows, request a free, no-obligation demonstration with the Medigen Suite team.
Frequently Asked Questions
Are decentralized clinical trials always conducted remotely?
No. Decentralized clinical trials may incorporate selected remote activities while maintaining traditional site visits for procedures requiring direct clinical supervision. This is commonly described as a hybrid approach. The appropriate arrangement depends on participant safety, investigational product characteristics, study endpoints, regulatory requirements, and operational feasibility. A study does not need to be fully virtual to incorporate decentralized elements.
Do the benefits of decentralized clinical trials include lower study costs?
Decentralized approaches may reduce certain costs associated with participant travel, physical visits, and site-based activities, but overall savings are not guaranteed. Sponsors must also consider technology, logistics, participant support, training, oversight, and data management expenses. Financial benefits depend on the study design, participant population, selected activities, and implementation model. A study-specific cost assessment is therefore essential.
Can electronic informed consent replace in-person consent discussions?
Electronic informed consent can support the consent process when applicable regulatory and ethical requirements are met. However, digitizing the documentation does not eliminate the need to ensure that participants understand the study and have opportunities to ask questions. Depending on the research setting and jurisdiction, these interactions may take place remotely or in person, with appropriate safeguards and oversight.
What is the difference between ePRO and eCOA in decentralized studies?
ePRO refers to patient-reported outcome data collected electronically and directly from participants, without interpretation by another person. eCOA is a broader category of electronic clinical outcome assessments that includes ePRO and other assessment types. In decentralized studies, these methods may support remote data collection when the instruments, devices, and study procedures are suitable for the intended purpose.
How can sponsors maintain data quality when collecting information remotely?
Sponsors can support remote data quality through fit-for-purpose assessments, documented procedures, appropriate system controls, participant training, and ongoing data review. Relevant considerations include missing entries, data provenance, device suitability, assessment timing, and clinical escalation processes. The chosen technology must be evaluated within the complete study workflow, including responsibilities for monitoring and resolving data issues.
What should sponsors consider before implementing decentralized elements internationally?
Sponsors should assess the applicable regulatory requirements in each participating country, including rules for remote consent, local healthcare providers, clinical procedures, data protection, and cross-border activities. The study protocol and operational documentation should describe relevant responsibilities and safeguards. Requirements differ by jurisdiction and study type, so an approach accepted in one country cannot automatically be assumed acceptable elsewhere.
Sources
- U.S. Food and Drug Administration (FDA). Conducting Clinical Trials With Decentralized Elements. Final Guidance, September 2024. Official FDA guidance
- Miyata BL, Tafuto B, Jose N. Methods and perceptions of success for patient recruitment in decentralized clinical studies. Journal of Clinical and Translational Science, 2023. DOI: 10.1017/cts.2023.643. PubMed
- European Commission, Heads of Medicines Agencies, European Medicines Agency. Recommendation Paper on Decentralised Elements in Clinical Trials. Updated October 1, 2025. European Commission, EudraLex Volume 10 update | Official recommendation (Section 5, p. 17)
- FDA and Office for Human Research Protections (OHRP). Use of Electronic Informed Consent in Clinical Investigations: Questions and Answers. Final Guidance, December 2016. Official FDA guidance
- FDA. Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers. Final Guidance, October 2024. Official FDA guidance
- International Council for Harmonisation (ICH). ICH E6(R3) Good Clinical Practice. Principles and Annex 1 adopted January 2025; Annex 2 adopted June 3, 2026. Annex 2 adopted by CHMP June 25, 2026; EU effective date January 15, 2027. ICH Efficacy Guidelines | ICH Annex 2 | EMA implementation
Table of Contents
Latest Articles
This article provides general information and does not constitute regulatory, legal, clinical, or compliance advice. Requirements and appropriate processes may vary by study, product, jurisdiction, and organization. Medigen Suite functionality should be used in accordance with applicable regulations, study documentation, and internal procedures.




